$AUROPHARMA

Aurobindo Pharma are expected to remain in focus after the company secured final approval from the US Food and Drug Administration (USFDA) to manufacture and market Tofacitinib Tablets in 5 mg and 10 mg strengths. The product is the generic equivalent of Xeljanz Tablets, originally developed by PF Prism C.V. The approved medication is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis, active psoriatic arthritis, and moderately to severely active ulcerative colitis (UC). Aurobindo Pharma stated that the drug will be manufactured at APL Healthcare Unit IV, its wholly owned subsidiary, with an immediate commercial launch planned in the US market. In another significant development, the company on June 3 inaugurated TheraNym, one of India’s largest dedicated biologics contract manufacturing organisations (CMOs), strengthening its presence in the fast-growing biologics segment. On the stock performance front, Aurobindo Pharma shares hit a 52-week high of ₹1,550 on May 21, 2026, and a 52-week low of ₹1,017 on September 2, 2025. The stock is currently trading 5.57% below its 52-week high and 43.91% above its 52-week low.